SecBot SecBot
S-3ASR ·Filed Jun 18, 2026

TWST

Twist Bioscience Corp
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001104659-26-075726
Notable filing: S-3ASR
Actionable Insight • Neutral

Monitor actual ATM sales volume and pace; the company has broad discretion over timing and amount. No immediate catalyst, watch for subsequent prospectus supplements or 10-Q disclosures revealing utilization. The ATM provides financial flexibility but will dilute existing holders over time.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$85.17
T+0 close · Jun 18, 2026 · via day close
Latest settled
+62.15%
T+60 · $138.10
Vs SPY
+60.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $85.17entry
  2. T+1 · 5mo ago −0.20%α +1.25% · $85.00
  3. T+5 · 5mo ago +17.22%α +19.29% · $99.84
  4. T+20 · 4mo ago +10.19%α +10.34% · $93.85
  5. T+60 · 2mo ago +62.15%α +60.40% · $138.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Twist Bioscience filed an automatic shelf registration (S-3ASR) including a base prospectus for various securities and a specific at-the-market (ATM) offering of up to $200M of common stock through TD Cowen. The ATM provides flexible capital-raising capacity for general corporate purposes, representing ~3.8% of the current $5.2B market cap. The filing is routine for a well-known seasoned issuer and does not indicate financial distress.

Key Facts

  • S-3ASR filed June 18, 2026, as a well-known seasoned issuer
  • Includes ATM sales agreement for up to $200M of common stock through TD Cowen
  • TD Cowen commission capped at 3% of gross proceeds
  • Net proceeds to be used for working capital and general corporate purposes
  • As of March 31, 2026: 62,154,412 shares outstanding; net tangible book value $359.9M ($5.79/share)
  • Pro forma dilution of $76.37/share at assumed $84.95 offering price
  • Company has no current commitments for acquisitions or specific use of proceeds

Financial Impact

Up to $200M gross proceeds; ~3.8% dilution relative to $5.2B market cap; pro forma net tangible book value increases to ~$553.3M ($8.58/share)

dilutionshare countcash and marketable securities

Risk Factors

  • Potential dilution from future ATM sales at uncertain prices
  • Stock price pressure from continuous offering overhang
  • Management discretion over proceeds may lead to value-destructive uses

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001104659-26-075726
Document: tm2617605-1_s3asr.htm0001104659-26-075726
Document: tm2617605d2_ex1-2.htm0001104659-26-075726

US Market Status

Market Open · Closes in 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026